Diagnostics company sphingotec has secured 5 million funding from Brandenburg Kapital, a subsidiary of ILB, and a Swiss family office

Innovative biomarkers for predicting and monitoring of life-threatening situations in intensive care patients


Ansprechpartner


Petra Quehl Project Coordinator